• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化巨大垂体腺瘤的内镜及联合手术策略:对过去一年49例病例的三级中心评估

Refining Endoscopic and Combined Surgical Strategies for Giant Pituitary Adenomas: A Tertiary-Center Evaluation of 49 Cases over the Past Year.

作者信息

Emengen Atakan, Yilmaz Eren, Gokbel Aykut, Uzuner Ayse, Balci Sibel, Tavukcu Ozkan Sedef, Ergen Anil, Caklili Melih, Cabuk Burak, Anik Ihsan, Ceylan Savas

机构信息

Department of Neurosurgery, Bahcesehir University School of Medicine, 34734 Istanbul, Turkey.

Department of Neurosurgery, VM Pendik Medical Park Hospital, 34899 Istanbul, Turkey.

出版信息

Cancers (Basel). 2025 Mar 26;17(7):1107. doi: 10.3390/cancers17071107.

DOI:10.3390/cancers17071107
PMID:40227627
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11987817/
Abstract

: Giant pituitary adenomas (GPAs) pose significant surgical challenges due to their large size, parasellar/suprasellar extensions, and proximity to critical neurovascular structures. Although the endoscopic endonasal approach (EEA) is preferred for pituitary tumors, achieving gross total resection (GTR) in GPAs remains difficult. Additional transcranial approaches may improve resection rates while minimizing morbidity. This study evaluates the impact of endoscopic and combined surgical approaches on resection outcomes using a classification system previously defined in GPA patients treated over the past year. : Among 517 pituitary adenomas treated in our clinic between September 2023 and September 2024, 49 GPA patients underwent endoscopic endonasal, transcranial, or combined surgery. Their medical records and surgical videos were retrospectively reviewed. Data included demographics, symptoms, imaging, surgical details, and follow-up outcomes. Tumor resection rates were analyzed based on the "landmark-based classification", considering radiological and pathological features and surgical approach. : The mean age was 45.5 years (female/male: 14/35). Zone distribution was 8 (Zone 1), 21 (Zone 2), and 20 (Zone 3). GTR was achieved in 34.6%, near-total resection in 36.7%, and subtotal resection in 28.5%. Endoscopic surgery was performed in 41 patients, combined surgery in 7, and a transcranial approach in 1. Complications included diabetes insipidus (9/49), cerebrospinal fluid leakage (2/49), apoplexy (2/49), hypocortisolism (3/49), epidural hematoma (1/49), and epistaxis (1/49). : While EEA is effective for Zone 1 and 2 GPAs, Zone 3 tumors often require combined or transcranial approaches for better resection. A multimodal strategy optimizes tumor removal while minimizing morbidity. Individualized surgical planning based on tumor classification is crucial for improving outcomes.

摘要

巨大垂体腺瘤(GPA)因其体积大、鞍旁/鞍上扩展以及靠近关键神经血管结构而带来重大手术挑战。尽管内镜鼻内入路(EEA)是垂体肿瘤的首选方法,但在GPA中实现全切除(GTR)仍然困难。额外的经颅入路可能会提高切除率,同时将发病率降至最低。本研究使用先前为过去一年接受治疗的GPA患者定义的分类系统,评估内镜和联合手术入路对切除结果的影响。:在2023年9月至2024年9月期间在我们诊所治疗的517例垂体腺瘤中,49例GPA患者接受了内镜鼻内、经颅或联合手术。对他们的病历和手术视频进行了回顾性审查。数据包括人口统计学、症状、影像学、手术细节和随访结果。基于“基于地标分类”分析肿瘤切除率,同时考虑放射学和病理学特征以及手术入路。:平均年龄为45.5岁(女性/男性:14/35)。区域分布为8例(1区)、21例(2区)和20例(3区)。GTR实现率为34.6%,近全切除率为36.7%,次全切除率为28.5%。41例患者接受了内镜手术,7例接受了联合手术,1例接受了经颅入路。并发症包括尿崩症(9/49)、脑脊液漏(2/49)、卒中(2/49)、皮质醇减退(3/49)、硬膜外血肿(1/49)和鼻出血(1/49)。:虽然EEA对1区和2区GPA有效,但3区肿瘤通常需要联合或经颅入路以实现更好的切除。多模式策略可优化肿瘤切除,同时将发病率降至最低。基于肿瘤分类的个体化手术规划对于改善结果至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/e22455b684f2/cancers-17-01107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/722d75f171ea/cancers-17-01107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/818cb2dec69a/cancers-17-01107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/e22455b684f2/cancers-17-01107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/722d75f171ea/cancers-17-01107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/818cb2dec69a/cancers-17-01107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb55/11987817/e22455b684f2/cancers-17-01107-g003.jpg

相似文献

1
Refining Endoscopic and Combined Surgical Strategies for Giant Pituitary Adenomas: A Tertiary-Center Evaluation of 49 Cases over the Past Year.优化巨大垂体腺瘤的内镜及联合手术策略:对过去一年49例病例的三级中心评估
Cancers (Basel). 2025 Mar 26;17(7):1107. doi: 10.3390/cancers17071107.
2
Endoscopic approach for giant pituitary adenoma: clinical outcomes of 205 patients and comparison of two proposed classification systems for preoperative prediction of extent of resection.内镜经鼻入路切除巨大垂体腺瘤:205 例患者的临床结果,并比较两种术前预测肿瘤全切除程度的分类系统。
J Neurosurg. 2021 Sep 17;136(3):786-800. doi: 10.3171/2021.3.JNS204116. Print 2022 Mar 1.
3
Endoscopic transcranial transdiaphragmatic approach in a single-stage surgery for giant pituitary adenomas.内镜经颅经膈入路一期手术治疗巨大垂体腺瘤
Front Oncol. 2023 Feb 1;13:1133861. doi: 10.3389/fonc.2023.1133861. eCollection 2023.
4
Endoscopic Endonasal Transtubercular Approach for Resection of Giant Pituitary Adenomas With Subarachnoid Extension: The "Second Floor" Strategy to Avoid Postoperative Apoplexy.经鼻内镜颅底入路切除伴有蛛网膜下腔侵犯的巨大垂体腺瘤:避免术后卒中的“第二层”策略。
World Neurosurg. 2021 Sep;153:e464-e472. doi: 10.1016/j.wneu.2021.06.142. Epub 2021 Jul 6.
5
Clinical Outcomes After Endoscopic Endonasal Resection of Giant Pituitary Adenomas.经鼻内镜切除巨大垂体腺瘤后的临床结局
World Neurosurg. 2018 Jun;114:e447-e456. doi: 10.1016/j.wneu.2018.03.006. Epub 2018 Mar 12.
6
Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection.经鼻内镜蝶窦入路切除大型和巨大型垂体腺瘤:机构经验和影响切除程度的预测因素。
J Neurosurg. 2014 Jul;121(1):75-83. doi: 10.3171/2014.3.JNS131679. Epub 2014 May 2.
7
Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas.经鼻内镜垂体腺瘤术后残留或复发的再次手术治疗。
J Neurosurg. 2017 Aug;127(2):397-408. doi: 10.3171/2016.8.JNS152709. Epub 2016 Oct 28.
8
Outcomes and surgical nuances in management of giant pituitary adenomas: a review of 108 cases in the endoscopic era.巨大垂体腺瘤治疗的结果与手术细节:内镜时代108例病例回顾
J Neurosurg. 2022 Jan 21;137(3):635-646. doi: 10.3171/2021.10.JNS21659. Print 2022 Sep 1.
9
Primary Endoscopic Endonasal Management of Giant Pituitary Adenomas: Outcome and Pitfalls from a Large Prospective Multicenter Experience.巨大垂体腺瘤的初次鼻内镜鼻内治疗:来自大型前瞻性多中心经验的结果与陷阱
Cancers (Basel). 2021 Jul 18;13(14):3603. doi: 10.3390/cancers13143603.
10
Surgical management of giant pituitary adenomas: institutional experience and clinical outcomes of 94 patients.巨大垂体腺瘤的手术治疗:94例患者的机构经验及临床结果
Front Oncol. 2023 Nov 20;13:1255768. doi: 10.3389/fonc.2023.1255768. eCollection 2023.

引用本文的文献

1
Endoscopic Transsphenoidal Sellar Surgery via One Nostril: Own Experience and Systematic Review of the Literature.经单鼻孔的内镜经蝶鞍手术:自身经验及文献系统综述
Life (Basel). 2025 Aug 4;15(8):1233. doi: 10.3390/life15081233.

本文引用的文献

1
Successful Multimodal Management of an Aggressive Functional Gonadotropic Pituitary Macroadenoma.侵袭性促性腺激素垂体大腺瘤的成功多模式管理
AACE Clin Case Rep. 2024 Sep 12;11(1):14-17. doi: 10.1016/j.aace.2024.09.003. eCollection 2025 Jan-Feb.
2
Giant and irregular pituitary neuroendocrine tumors surgery: comparison of simultaneous combined endoscopic endonasal and transcranial and purely endoscopic endonasal surgery at a single center.巨大及不规则垂体神经内分泌肿瘤手术:单中心同期联合鼻内镜经鼻与经颅手术及单纯鼻内镜经鼻手术的比较
Chin Neurosurg J. 2025 Feb 3;11(1):3. doi: 10.1186/s41016-025-00389-4.
3
Single-cell transcriptomics identify a novel macrophage population associated with bone invasion in pituitary neuroendocrine tumors.
单细胞转录组学鉴定出与垂体神经内分泌肿瘤骨侵袭相关的新型巨噬细胞群体。
J Exp Clin Cancer Res. 2025 Jan 27;44(1):27. doi: 10.1186/s13046-025-03296-9.
4
Different types of combined endoscopic and transcranial approaches for complex giant pituitary adenomas: how I do it.不同类型的联合内镜和经颅入路治疗复杂巨大垂体腺瘤:我的方法。
Acta Neurochir (Wien). 2024 Nov 22;166(1):473. doi: 10.1007/s00701-024-06371-w.
5
Operative Nuances of Capsular Dissection Techniques and Capsule Morphology in Pituitary Adenomas: Past 1-Year Case Experiences of a Tertiary Center.垂体腺瘤中包膜剥离技术的手术细微差别及包膜形态:三级中心过去一年的病例经验
Oper Neurosurg (Hagerstown). 2024 Dec 1;27(6):681-689. doi: 10.1227/ons.0000000000001183. Epub 2024 May 8.
6
Clinical and Surgical Outcomes of Endoscopic Endonasal Approach for Giant Pituitary Adenomas: Analysis of Predictive Factors.内镜经鼻入路治疗巨大垂体腺瘤的临床和手术结果:预测因素分析。
World Neurosurg. 2024 Apr;184:e659-e673. doi: 10.1016/j.wneu.2024.02.009. Epub 2024 Feb 9.
7
Surgical Strategies in the Treatment of Giant Pituitary Adenomas.巨大垂体腺瘤治疗中的手术策略
Oper Neurosurg. 2024 Jan 1;26(1):4-15. doi: 10.1227/ons.0000000000000896. Epub 2023 Sep 1.
8
The evolution in pituitary tumour classification: a clinical perspective.垂体肿瘤分类的演变:临床视角
Endocr Oncol. 2023 Apr 21;3(1):e220079. doi: 10.1530/EO-22-0079. eCollection 2023 Jan 1.
9
Outcome of giant pituitary tumors requiring surgery.需要手术的巨大垂体瘤的结果。
Front Endocrinol (Lausanne). 2022 Aug 29;13:975560. doi: 10.3389/fendo.2022.975560. eCollection 2022.
10
Clinical Biology of the Pituitary Adenoma.垂体腺瘤的临床生物学。
Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.